Lazard Asset Management
KRTX

Lazard Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Lazard Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-490
Closed -$82K – 2532
2023
Q3 		$82K Buy
490
+265
+118% +$49.8K ﹤0.01% 1698
2023
Q2 		$48K Buy
+225
New +$48.2K ﹤0.01% 1849
2022
Q2 		– Sell
-688
Closed -$87K – 2624
2022
Q1 		$87K Buy
+688
New +$77.5K ﹤0.01% 1460

Other funds holding KRTX

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Lazard Asset Management's KRTX Position: Q4 2023 in Review

Lazard Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2023, closing a stake of 490 shares — an estimated $82K sold.

Lazard Asset Management first reported a position in KRTX in Q1 2022 and held it in 3 quarters. The position peaked at $87K in Q1 2022. 328 funds tracked by Wall St. Rank hold KRTX as of Q4 2023.

  • Lazard Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Lazard Asset Management sold 490 Karuna Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $82K.
  • Lazard Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Lazard Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $87K in Q1 2022.
  • 328 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Lazard Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.